Scholarlink

<p>Endometrial Cancer is a prevalent malignant tumor in gynecology, marked by high incidence and poor prognosis. The discovery of cuproptosis, a copper-dependent cell death pathway, offers new therapeutic potential. We systematically reviewed literature on cuproptosis mechanisms in endometrial cancer, including copper metabolism dysregulation, prognostic biomarkers, and therapeutic strategies. Then we identified three key findings: (1) Copper homeostasis disruption promotes cancer via angiogenesis, metastasis, and chemoresistance; (2) Cyclin-dependent kinase inhibitor 2&#xa0;A and glutaminase exhibit strong prognostic predictive value; (3) The strategy of regulating copper homeostasis exhibits anticancer effects. Cuproptosis targeting represents a promising strategy for endometrial cancer management. Further clinical validation of cuproptosis-related biomarkers and optimization of combination therapies are warranted.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Targeting cuproptosis for treatment and prognostic assessment in endometrial cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月28日

查看全文
  • Jie Yu,
  • Huan Shi,
  • Jingxia Zhang,
  • Weiyan Shan,
  • Qiaoping Xu,
  • Hongkai Shang

摘要

Endometrial Cancer is a prevalent malignant tumor in gynecology, marked by high incidence and poor prognosis. The discovery of cuproptosis, a copper-dependent cell death pathway, offers new therapeutic potential. We systematically reviewed literature on cuproptosis mechanisms in endometrial cancer, including copper metabolism dysregulation, prognostic biomarkers, and therapeutic strategies. Then we identified three key findings: (1) Copper homeostasis disruption promotes cancer via angiogenesis, metastasis, and chemoresistance; (2) Cyclin-dependent kinase inhibitor 2 A and glutaminase exhibit strong prognostic predictive value; (3) The strategy of regulating copper homeostasis exhibits anticancer effects. Cuproptosis targeting represents a promising strategy for endometrial cancer management. Further clinical validation of cuproptosis-related biomarkers and optimization of combination therapies are warranted.